Precision Gene Editing with Adenine Base Editors Restores Muscle Function in Childhood FSHD Model, Advancing Gene Therapy

bioRxiv Australia

Overview

This study presents a novel therapeutic strategy for childhood-onset Facioscapulohumeral Muscular Dystrophy (FSHD), an intractable genetic disorder. Researchers leveraged an iPSC-derived skeletal muscle model to demonstrate that adenine base editing (ABE) precisely targeting the pathogenic DUX4 gene significantly suppresses its expression and improves crucial muscle function indicators, such as cross-sectional area and force generation. These findings not only validate DUX4 gene editing as a promising therapeutic avenue but also highlight the utility of iPSC models for non-invasive FSHD research and future drug development.

In Depth

Background

Muscular dystrophies represent a challenging class of genetic disorders, uniformly characterized by progressive muscle weakness and often lacking effective treatments. Facioscapulohumeral Muscular Dystrophy (FSHD) stands as a prominent example, severely diminishing patients’ quality of life. However, the landscape of treatment for these intractable conditions is rapidly evolving, with recent breakthroughs in genome editing technologies—such as the approval of gene therapies for Duchenne muscular dystrophy—igniting new hope for patients.

FSHD originates from the aberrant expression of the DUX4 gene within skeletal muscle. While DUX4 is typically active only during embryonic development, its pathological expression in FSHD patients—often triggered by contraction of the D4Z4 repeat array or mutations in the SMCHD1 gene—produces a protein toxic to muscle cells, resulting in progressive muscle weakness. Consequently, suppressing DUX4 expression stands as a fundamental therapeutic strategy for FSHD.

At the heart of this therapeutic approach is Adenine Base Editing (ABE), a precision genome editing technology. Unlike conventional CRISPR/Cas9 systems that induce DNA double-strand breaks, ABE directly converts adenine (A) to guanine (G) without creating such breaks. This capability enables highly precise modifications, such as correcting specific mutations within the DUX4 gene or altering its transcription initiation sites to suppress its expression. The key advantage of ABE lies in its reduced off-target risk and lower cellular toxicity compared to double-strand break-inducing methods, making it a safer and more precise tool for gene correction.

The development and application of patient-derived iPSC-generated 2D/3D skeletal muscle models are crucial to this research. These sophisticated in vitro models accurately recapitulate the complex pathophysiology of FSHD, offering an efficient and ethical platform for evaluating potential therapies. This is particularly vital for rare diseases such as childhood-onset FSHD, where patient-specific cellular models are indispensable for accelerating fundamental research and preclinical drug development without invasive procedures on patients.

Key Findings

In a significant step towards a cure for childhood-onset FSHD, this study successfully developed and utilized a novel iPSC (induced pluripotent stem cell)-derived skeletal muscle model, specifically tailored for the childhood-onset form known to correlate with increased disease severity. This advanced model served as a crucial platform to evaluate the therapeutic potential of adenine base editing (ABE) precisely targeting the pathogenic DUX4 gene.

The findings were striking: ABE not only significantly reduced DUX4 mRNA expression but also led to substantial improvements in critical muscle function parameters, including muscle cross-sectional area and force generation. These results provide compelling evidence for the efficacy of DUX4-targeted ABE in mitigating FSHD pathogenesis at a cellular level.

This pioneering work strongly substantiates the value of iPSC-derived disease models for non-invasive investigation into the pathophysiology of childhood-onset FSHD. Crucially, it validates DUX4 gene editing as an exceptionally promising therapeutic strategy for FSHD, opening new avenues for gene therapy development.

Looking forward, the immediate next steps involve rigorous in vivo validation of DUX4-targeted ABE’s safety and efficacy, including thorough assessments of long-term muscle function improvement, potential off-target effects, and immunogenicity. This research not only accelerates the path towards clinical application for childhood-onset FSHD but also reinforces the broader utility of iPSC-derived models in developing therapies for a spectrum of muscular dystrophies and other genetic diseases.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime